Compare Bitwise Crypto Industry Innovators ETF (BITQ) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bitwise Crypto Industry Innovators ETF vs GeneDx Holdings Corp — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $22.36, while GeneDx Holdings Corp trades at $81.98 (market cap $2.44B). Which is the better fit depends on your goals.
| BITQ | WGS | |
|---|---|---|
Sector | Crypto-linked | Technology |
52-Week High | $30.43 | $167.51 |
52-Week Low | $16.74 | $34.51 |
Market Cap | — | $2.44B |
Enterprise Value | — | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BITQ trades at $22.88, up 1.42% today, but faces strong technical headwinds with 17 sell signals versus 0 buy signals across moving averages and oscillators. The stock shows bearish momentum with key resistance at $23 and support at $22. Financial metrics remain unavailable in current data, requiring verification through SEC filings.
The technical outlook appears bearish with weak momentum indicators. Investment opportunity depends on upcoming earnings clarity and institutional positioning. Primary risks include market volatility and lack of visible fundamental support until financial disclosures are updated.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bitwise Crypto Industry Innovators ETF
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
